Abstracts tagged "measure and rheumatoid arthritis (RA)"

Abstract Number: 327 • 2018 ACR/ARHP Annual Meeting
The Patient Global Assessment and Common Composite Disease Activity Measures Vary Minimally When Patients Reflect on Their Arthritis or Their Global Health: Results from the Canadian Early Arthritis Cohort Study
Vivian P. Bykerk¹, Orit Schieir², Marie-France Valois³, Edward C. Keystone⁴, Gilles Boire⁵, Janet E. Pope⁶, Diane Tin⁷, Carol Hitchon⁸, Carter Thorne⁹, Susan J. Bartlett¹⁰ and Boulos Haraoui¹¹, ¹Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ²McGill University, Montreal, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine, University of Western Ontario, London, ON, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto, Newmarket, ON, Canada, ¹⁰Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada
Background/Purpose: The patient global assessment (PtGA) is a core domain used in RA composite disease activity (CDA) measures for trials and treat-2-target paradigms. The PtGA…
Abstract Number: 1469 • 2018 ACR/ARHP Annual Meeting
Measurement of Anti-Amyloid β Autoantibodies in Patients with Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Tomohisa Tani³ and Toshiro Ohashi³, ¹R, Ohashi-Tani Orthopaedic, Gifu, Japan, ²Advanced Diagnostic System Research Laboratory, Fujita Health University, Toyoake, Japan, ³Ohashi-Tani Orthopaedic, Gifu, Japan
Background/Purpose: Amyloid β (Aβ) accumulation in the brain is a risk factor for Alzheimer's disease (AD). The incidence of AD increases with age. Rheumatoid arthritis…
Abstract Number: 2860 • 2018 ACR/ARHP Annual Meeting
Disease Activity and Its Measurement in Patients with RA across the U.S.: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk^1,2, Michael Evans³, Julia Kay¹, Lisa Gale Suter⁴, Megan E. B. Clowse⁵, Esi Morgan⁶, Andreas Reimold⁷, Alex Limmani⁸, Tracy Johansson⁹, Lindsay Lewis⁹ and Jinoos Yazdany¹⁰, ¹Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, San Francisco, CA, ³University of California - San Francisco, San Francisco, CA, ⁴Rheumatology, Rheumatology, Yale University School of Medicine, New Haven, CT, New Haven, CT, ⁵Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ⁶University of Cincinnati, Cincinnati, OH, ⁷Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ⁸Arthritis Centers of Texas, Dallas, TX, ⁹Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ¹⁰University of California, San Francisco, San Francisco, CA
Background/Purpose: Although national quality measures promote the measurement of disease activity (DA) in RA, the burden of DA in a population-based sample of RA patients…
Abstract Number: 1802 • 2017 ACR/ARHP Annual Meeting
Detection of Flare over the Past 3 Months in Rheumatoid Arthritis: Cross-Cultural Equivalence of the Self-Report Flare-RA Questionnaire
Francis Guillemin¹, Marie-Line Erpelding², Annette de Thurah^3,4,5,6, Elena Myasoedova⁷, Emilce E Schneeberger⁸, Cynthia S. Crowson⁹, Thomas Maribo¹⁰, Gustavo Citera¹¹, Eric L. Matteson¹² and Bruno Fautrel¹³, ¹University of Lorraine, Nancy, France, Nancy, France, ²CIC 1433 Clinical Epidemiology, Inserm, Nancy, France, ³Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁶Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ⁷Rheumatology, Mayo Clinic, Rochester, MN, ⁸Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁹Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁰DEFACTUM, Central Region Denmark, Aarhus, Denmark, ¹¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹³UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: The Flare-RA questionnaire was developed and validated in French (1) for assessing the occurrence of a flare of rheumatoid arthritis (RA) during a 3-month…
Abstract Number: 450 • 2016 ACR/ARHP Annual Meeting
Coming Full Circle with the Omeract RA Flare Questionnaire (RA-FQ): Further Evaluation of the Properties, Meaningfulness, and Utility through Rasch Analysis and Feedback from RA Patients
Susan J. Bartlett^1,2, Skye Barbic³, Vivian P. Bykerk⁴, Bruno Fautrel⁵, Francis Guillemin⁶, A den Broeder⁷, R Alten⁸, Robin Christensen⁹, Ernest H. Choy¹⁰, Daniel E. Furst¹¹, Sarah Hewlett¹², Amye L. Leong¹³, Lyn March¹⁴, Thasia G Woodworth¹⁵, Clifton Bingham III¹⁶ and OMERACT Flare Group and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of British Columbia, Vancouver, BC, Canada, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁶University of Lorraine, Nancy, France, ⁷Rheumatology, Maartenskliniek, Nijmegen, Netherlands, ⁸Schlosspark-Klinik University Medicine, Berlin, Germany, ⁹The Parker instutute, RC, Copenhagen, Denmark, ¹⁰Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ¹¹University of California, Los Angeles, Los Angeles, CA, ¹²Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹³Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹⁴Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹⁵Leading Edge Clinical Research, Stuart, FL, ¹⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: OMERACT Filter 2.0 encourages use of robust methods to develop new measures. Instrument results also should be highly relevant, easily scored and interpreted, and…
Abstract Number: 2655 • 2015 ACR/ARHP Annual Meeting
Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare
VP Bykerk^1,2, Clifton O. Bingham III³, Ernest H. Choy⁴, Daming Lin², Rieke Alten⁵, Robin Christensen⁶, Daniel E. Furst⁷, Francis Guillemin⁸, Sarah Hewlett⁹, Amye L. Leong¹⁰, Lyn March¹¹, Thasia Woodworth¹², Gilles Boire¹³, Carol Hitchon¹⁴, Shahin Jamal¹⁵, Edward C. Keystone¹⁶, Janet E. Pope¹⁷, J Carter Thorne¹⁸, Diane Tin¹⁹, Susan J. Bartlett^20,21,22 and CATCH Investigators and OMERACT Flare Group, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁵Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁶The Parker instutute, RC, Copenhagen, Denmark, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸University of Lorraine, Nancy, France, ⁹Academic Rheumatology, University of West of England, Bristol, United Kingdom, ¹⁰Spokesperson; Strategic Relations, BONE AND JOINT DECADE, Santa Barbara, CA, ¹¹Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹²Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ¹³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ¹⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁷Monsignor Roney Bldg/Rheum, University of Western Ontario, St Joseph Health Care, London, ON, Canada, ¹⁸University of Toronto, Toronto, ON, Canada, ¹⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ²⁰Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²²Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: A reference point for clinically important worsening (CIW) of RA disease activity requiring retreatment or escalation is needed for randomized trials of treatment withdrawal.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].